

**Table 13.6i**  
**Immunosuppression Use for Antirejection Treatment from Transplant**  
**to One Year Following Transplantation, 1998 to 2007**  
**Recipients with Heart-Lung Transplants**

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>Transplants</b>	47	51	48	27	33	29	40	35	31	31
<b>Tx with Antirejection Treatments</b>	25	18	16	4	8	8	12	10	13	6
<b>Antibodies</b>										
Any in Category	20.0%	5.6%	18.8%	0.0%	0.0%	12.5%	16.7%	0.0%	38.5%	0.0%
Atgam/NRATG/NRATS	16.0%	0.0%	6.3%	0.0%	0.0%	12.5%	0.0%	0.0%	15.4%	0.0%
Thymoglobulin	4.0%	5.6%	0.0%	0.0%	0.0%	0.0%	16.7%	0.0%	15.4%	0.0%
Zenapax	0.0%	0.0%	12.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.7%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.7%	0.0%
<b>Corticosteroids</b>										
Any in Category	92.0%	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%	100.0%	100.0%	100.0%
Steroids	92.0%	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%	100.0%	100.0%	100.0%
<b>Antimetabolites</b>										
Any in Category	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.